Get started
Author

Marie Meurer

Effective Management of Advanced Angiosarcoma by the Synergistic Combination of Propranolol and Vinblastine-based Metronomic Chemotherapy: A Bench to Bedside Study
2016 · Eddy Pasquier, Nicolas André, et al. · EBioMedicine · 125
PDF
R-propranolol is a small molecule inhibitor of the SOX18 transcription factor in a rare vascular syndrome and hemangioma
2019 · Jeroen Overman, Frank Fontaine, et al. · eLife · 65
Olaparib and durvalumab in patients with relapsed small cell lung cancer (MEDIOLA): An open-label, multicenter, phase 1/2, basket study
2023 · Matthew G. Krebs, Jean-Pierre Delord, et al. · Lung Cancer · 42
PDF
Localized high grade endometrial stromal sarcoma and localized undifferentiated uterine sarcoma: a retrospective series of the French Sarcoma Group
2019 · Marie Meurer, A Floquet, et al. · International Journal of Gynecological Cancer · 36
VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor–Positive/HER2−/PIK3CA Wild-Type Advanced Breast Cancer
2026 · Sara A. Hurvitz, Rachel M. Layman, et al. · Journal of Clinical Oncology · 19
Selpercatinib (LOXO-292) in patients with RET-mutant medullary thyroid cancer.
2020 · Manisha H. Shah, Eric Jeffrey Sherman, et al. · Journal of Clinical Oncology · 14
118MO Trastuzumab deruxtecan (T-DXd) and pembrolizumab in immuno-oncology (IO)-naive HER2-expressing or HER2-mutant non-small cell lung cancer (NSCLC): Interim analysis of a phase Ib study
2024 · A. Italiano, B. Besse, et al. · Immuno-Oncology Technology · 12
PDF
Prognostic Value of the B12/CRP Index in Older Systemically Treatable Cancer Patients
2021 · Coline Montegut, Florian Correard, et al. · Cancers · 9
PDF
LBA8 Precision immuno-oncology for advanced non-small cell lung cancer (NSCLC) patients with PD-(L)1 inhibitors resistance (PIONeeR): A phase Ib/IIa clinical trial targeting identified resistance pathways
2024 · P. Tomasini, C. Cropet, et al. · Annals of Oncology · 5
Abstract P5-07-29: Trastuzumab deruxtecan With Pembrolizumab in Previously Treated HER2-Expressing Advanced or Metastatic Breast Cancer: Interim Analyses of the Breast Cohorts from the Open-Label, Multicenter, Phase 1b Study DS8201-A-U106
2025 · Hope S. Rugo, Antonio Anton Torres, et al. · Clinical Cancer Research · 3
Undifferentiated endometrial sarcomas (UES): Results of a French sarcoma group (FSG) retrospective series of 52 patients (pts).
2017 · Marie Meurer, Anne Floquet, et al. · Journal of Clinical Oncology · 2
Primary ovarian leiomyosarcoma: results from an analysis by the French Sarcoma Group (Ovarian SArcoma MAnagement – OSAMA Study)
2025 · Domenico Ferraioli, Fulvio Borella, et al. · International Journal of Gynecological Cancer · 1
PDF
Étude de cohorte évaluant la toxicité cutanée des anticorps bispécifiques anti-EGFR et anti-MET seuls ou en association aux inhibiteurs d’EGFR
2023 · E. Connell, C. Sarles, et al. · Annales de Dermatologie et de Vénéréologie - FMC · 1
O10-3 Selpercatinib (LOXO-292) in patients (pts) with RET-altered thyroid cancer
2021 · Lori J. Wirth, Eric J. Sherman, et al. · Annals of Oncology · 1
Author response: R-propranolol is a small molecule inhibitor of the SOX18 transcription factor in a rare vascular syndrome and hemangioma
2019 · Jeroen Overman, Frank Fontaine, et al. · 1
Chemotherapy with or without pembrolizumab followed by maintenance pembrolizumab with or without olaparib as first-line treatment of patients with advanced BRCA non-mutated epithelial ovarian cancer (ENGOT-OV43/GOG-3036/KEYLYNK-001): a randomised, double-blind, placebo-controlled, phase 3 trial
2026 · Ignace Vergote, Ignace Vergote, et al. · The Lancet Oncology
IMMUNORARE 5 : A national platform of 5 academic phase II trials coordinated by Lyon University Hospital to assess the safety and the efficacy of the immunotherapy with domvanalimab + zimberelimab combination in patients with advanced rare cancers—The Gestational Trophoblastic Tumors Cohort.
2025 · Benoit You, Alexandra Leary, et al. · Journal of Clinical Oncology
Clinical Management, Prognostic Factors And Oncologic Outcome Of Primary Ovarian Leiomyosarcomas (OSAMA Study). A French Sarcoma Group Study
2025 · Domenico Ferraioli, Marie Meurer, et al. · International Journal of Gynecological Cancer
Un cas de dermite de rappel sous immunothérapie anti-PDL1
2023 · L. Fourcade, F. Duffaut, et al. · Annales de Dermatologie et de Vénéréologie - FMC
Selpercatinib (LOXO-292) in patients with RET-mutant medullary thyroid cancer (MTC)
2020 · Momin Shah, Eric J. Sherman, et al.
Localized undifferentiated endometrial sarcomas (LUES): Results of a French Sarcoma Group (FSG) retrospective series of 39 patients (pts)
2017 · M. Meurer, F. Duffaud, et al. · Annals of Oncology
PDF
Works count: 21
Citation count: 336
H-index: 8
I10-index: 7
Year
Topic
Type